COVID-19 Has ‘Permanently Changed’ How The EMA Works
Executive Summary
During the pandemic, the EU drugs regulator became more flexible and agile and went beyond the formal boundaries of its mandate, says its executive director Emer Cooke, who also warns of the need for the agency to retain the trust of the public.
You may also be interested in...
EMA Agrees Monovalent XBB Vaccines Best For Coming COVID-19 Campaigns
The European Medicines Agency says it is talking with international partners and pharmaceutical companies about the epidemiological situation with SARS-CoV-2 and how authorized COVID-19 vaccines can best be adapted to emerging variants.
Misinformation Prompted Six Court Cases Against EU COVID-19 Vaccine Approvals In 2021
The EU’s conditional approval of four COVID-19 vaccines and its decision to extend the use of Pfizer/BioNTech’s Comirnaty to a younger age group were challenged in the court last year but the cases were declared inadmissible.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.